Does the media prefer PALI or XERS?

In the previous week, Xeris Biopharma had 7 more articles in the media than Palisade Bio. MarketBeat recorded 22 mentions for Xeris Biopharma and 15 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.48 beat Xeris Biopharma's score of 0.15 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PALI or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Avalyn Pharma N/A N/A N/A

Does the media prefer PALI or AVLN?

In the previous week, Palisade Bio had 6 more articles in the media than Avalyn Pharma. MarketBeat recorded 15 mentions for Palisade Bio and 9 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.72 beat Palisade Bio's score of 0.48 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LBRX or PALI more profitable?

LB Pharmaceuticals' return on equity of -25.92% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A -25.92% -24.68% Palisade Bio N/A -33.47% -31.79%

Does the media favor LBRX or PALI?

In the previous week, Palisade Bio had 5 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 15 mentions for Palisade Bio and 10 mentions for LB Pharmaceuticals. Palisade Bio's average media sentiment score of 0.48 beat LB Pharmaceuticals' score of 0.43 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ETON or PALI?

In the previous week, Eton Pharmaceuticals had 15 more articles in the media than Palisade Bio. MarketBeat recorded 30 mentions for Eton Pharmaceuticals and 15 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.48 beat Eton Pharmaceuticals' score of 0.40 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Palisade Bio 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, PALI or ARDX?

Palisade Bio has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palisade Bio $250K 1,491.75 -$16.78M -$1.01 N/A Ardelyx $407.32M 2.48 -$61.60M -$0.22 N/A

Is PALI or ARDX more profitable?

Palisade Bio has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Palisade Bio's return on equity of -33.47% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Ardelyx -12.35% -36.00% -10.77%

Does the media favor PALI or ARDX?

In the previous week, Ardelyx had 5 more articles in the media than Palisade Bio. MarketBeat recorded 20 mentions for Ardelyx and 15 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.48 beat Ardelyx's score of -0.27 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Palisade Bio (PALI) Competitors

$2.14 -0.01 (-0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$2.11 -0.03 (-1.40%)

As of 07:37 PM Eastern

Compare

PALI vs. XERS, AVLN, LBRX, ETON, and ARDX

Should you buy Palisade Bio stock or one of its competitors? Palisade Bio's main competitors and comparable companies include Xeris Biopharma (XERS), Avalyn Pharma (AVLN), LB Pharmaceuticals (LBRX), Eton Pharmaceuticals (ETON), and Ardelyx (ARDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Palisade Bio compare to Xeris Biopharma?

Palisade Bio (NASDAQ:PALI) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Xeris Biopharma has higher revenue and earnings than Palisade Bio. Xeris Biopharma is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,491.75	-$16.78M	-$1.01	N/A
Xeris Biopharma	$335.41M	4.67	$550K	-$0.11	N/A

Palisade Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xeris Biopharma had 7 more articles in the media than Palisade Bio. MarketBeat recorded 22 mentions for Xeris Biopharma and 15 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.48 beat Xeris Biopharma's score of 0.15 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palisade Bio has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Xeris Biopharma	-5.12%	338.21%	3.50%

Palisade Bio presently has a consensus target price of $9.00, suggesting a potential upside of 320.56%. Xeris Biopharma has a consensus target price of $10.80, suggesting a potential upside of 25.58%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Palisade Bio is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Palisade Bio beats Xeris Biopharma on 9 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Avalyn Pharma?

Palisade Bio (NASDAQ:PALI) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

In the previous week, Palisade Bio had 6 more articles in the media than Avalyn Pharma. MarketBeat recorded 15 mentions for Palisade Bio and 9 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.72 beat Palisade Bio's score of 0.48 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma has lower revenue, but higher earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,491.75	-$16.78M	-$1.01	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

Palisade Bio presently has a consensus price target of $9.00, suggesting a potential upside of 320.56%. Avalyn Pharma has a consensus price target of $60.00, suggesting a potential upside of 52.87%. Given Palisade Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Palisade Bio is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Avalyn Pharma's return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Avalyn Pharma	N/A	N/A	N/A

Summary

Palisade Bio beats Avalyn Pharma on 8 of the 12 factors compared between the two stocks.

How does Palisade Bio compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

LB Pharmaceuticals presently has a consensus target price of $47.75, indicating a potential downside of 0.06%. Palisade Bio has a consensus target price of $9.00, indicating a potential upside of 320.56%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palisade Bio has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Palisade Bio	$250K	1,491.75	-$16.78M	-$1.01	N/A

11.8% of Palisade Bio shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LB Pharmaceuticals' return on equity of -25.92% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Palisade Bio	N/A	-33.47%	-31.79%

In the previous week, Palisade Bio had 5 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 15 mentions for Palisade Bio and 10 mentions for LB Pharmaceuticals. Palisade Bio's average media sentiment score of 0.48 beat LB Pharmaceuticals' score of 0.43 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Palisade Bio beats LB Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Palisade Bio compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Eton Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Eton Pharmaceuticals has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$105.60M	15.27	-$4.60M	$0.38	154.89
Palisade Bio	$250K	1,491.75	-$16.78M	-$1.01	N/A

Eton Pharmaceuticals currently has a consensus price target of $67.50, suggesting a potential upside of 14.68%. Palisade Bio has a consensus price target of $9.00, suggesting a potential upside of 320.56%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Eton Pharmaceuticals had 15 more articles in the media than Palisade Bio. MarketBeat recorded 30 mentions for Eton Pharmaceuticals and 15 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.48 beat Eton Pharmaceuticals' score of 0.40 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Palisade Bio	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eton Pharmaceuticals has a net margin of 12.02% compared to Palisade Bio's net margin of 0.00%. Eton Pharmaceuticals' return on equity of 47.64% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	47.64%	12.93%
Palisade Bio	N/A	-33.47%	-31.79%

Summary

Eton Pharmaceuticals beats Palisade Bio on 10 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Ardelyx?

Palisade Bio (NASDAQ:PALI) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Palisade Bio has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,491.75	-$16.78M	-$1.01	N/A
Ardelyx	$407.32M	2.48	-$61.60M	-$0.22	N/A

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Ardelyx had 5 more articles in the media than Palisade Bio. MarketBeat recorded 20 mentions for Ardelyx and 15 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.48 beat Ardelyx's score of -0.27 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Palisade Bio has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Palisade Bio has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Palisade Bio's return on equity of -33.47% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Ardelyx	-12.35%	-36.00%	-10.77%

Palisade Bio presently has a consensus target price of $9.00, suggesting a potential upside of 320.56%. Ardelyx has a consensus target price of $15.00, suggesting a potential upside of 269.46%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Palisade Bio is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Palisade Bio beats Ardelyx on 10 of the 17 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PALI vs. The Competition

Export

Metric	Palisade Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$374.68M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-2.12	775.15	269.06	25.28
Price / Sales	1,491.75	741.16	592.96	87.71
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	3.06	11.60	12.91	6.24
Net Income	-$16.78M	$2.77B	$3.45B	$347.60M
7 Day Performance	1.42%	0.17%	1.12%	1.07%
1 Month Performance	10.88%	0.35%	1.79%	1.03%
1 Year Performance	162.58%	161.52%	67.69%	20.77%

Palisade Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PALI Palisade Bio	3.1527 of 5 stars	$2.14 -0.5%	$9.00 +320.6%	+165.2%	$374.68M	$250K	N/A	10	Earnings Report Analyst Revision
XERS Xeris Biopharma	3.463 of 5 stars	$8.19 +0.7%	$10.80 +31.9%	+14.5%	$1.41B	$291.85M	136.50	290	Analyst Downgrade Analyst Revision
AVLN Avalyn Pharma	4.2109 of 5 stars	$30.73 +7.8%	$59.00 +92.0%	N/A	$1.36B	N/A	N/A	51	News Coverage Earnings Report Analyst Forecast
LBRX LB Pharmaceuticals	0.727 of 5 stars	$45.00 +5.0%	$45.13 +0.3%	N/A	$1.29B	N/A	N/A	16	Earnings Report Analyst Downgrade High Trading Volume
ETON Eton Pharmaceuticals	3.5888 of 5 stars	$45.83 +1.5%	$52.50 +14.6%	+138.3%	$1.26B	$79.95M	N/A	20	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PALI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palisade Bio (PALI) Competitors

PALI vs. XERS, AVLN, LBRX, ETON, and ARDX

How does Palisade Bio compare to Xeris Biopharma?

Summary

How does Palisade Bio compare to Avalyn Pharma?

Summary

How does Palisade Bio compare to LB Pharmaceuticals?

Summary

How does Palisade Bio compare to Eton Pharmaceuticals?

Summary

How does Palisade Bio compare to Ardelyx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palisade Bio (PALI) Competitors

PALI vs. XERS, AVLN, LBRX, ETON, and ARDX

How does Palisade Bio compare to Xeris Biopharma?

Which has stronger valuation & earnings, PALI or XERS?

Which has more risk and volatility, PALI or XERS?

Do insiders & institutionals hold more shares of PALI or XERS?

Does the media prefer PALI or XERS?

Is PALI or XERS more profitable?

Do analysts prefer PALI or XERS?

Summary

How does Palisade Bio compare to Avalyn Pharma?

Does the media prefer PALI or AVLN?

Which has higher earnings and valuation, PALI or AVLN?

Do analysts recommend PALI or AVLN?

Do institutionals & insiders have more ownership in PALI or AVLN?

Is PALI or AVLN more profitable?

Summary

How does Palisade Bio compare to LB Pharmaceuticals?

Do analysts rate LBRX or PALI?

Which has better earnings & valuation, LBRX or PALI?

Do institutionals and insiders hold more shares of LBRX or PALI?

Is LBRX or PALI more profitable?

Does the media favor LBRX or PALI?

Summary

How does Palisade Bio compare to Eton Pharmaceuticals?

Which has more volatility & risk, ETON or PALI?

Which has better earnings & valuation, ETON or PALI?

Do analysts rate ETON or PALI?

Does the media prefer ETON or PALI?

Do institutionals & insiders hold more shares of ETON or PALI?

Is ETON or PALI more profitable?

Summary

How does Palisade Bio compare to Ardelyx?

Which has preferable earnings and valuation, PALI or ARDX?

Do institutionals & insiders hold more shares of PALI or ARDX?

Does the media favor PALI or ARDX?

Which has more risk & volatility, PALI or ARDX?

Is PALI or ARDX more profitable?

Do analysts recommend PALI or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools